ライフサイエンスコーパス: guanylate

1 es a reactive N-silylcarbodiimide capable of guanylating a variety of amines.

2 resence of manganese to form a covalent RtcB-guanylate adduct.

3 Here, we demonstrate that IFN-inducible guanylate binding protein (Gbp) proteins stimulate caspa

4 rticle, we show that the IFN-gamma-inducible guanylate binding protein 1 (GBP-1) is a regulator of T

5 Although GBP1 (guanylate binding protein 1) was among the first interfe

6 otein that stimulates inflammasome assembly: guanylate binding protein 5 (GBP5).

7 We have recently identified guanylate binding protein-1 (GBP-1) as an antiapoptotic

8 Members of the guanylate binding proteins (GBP) comprise the most abund

9 Guanylate binding proteins (GBPs) are an interferon (IFN

10 Furthermore, guanylate binding proteins (GBPs) encoded on chromosome

11 Interferon (IFN)-inducible guanylate binding proteins (GBPs) mediate cell-autonomou

12 ase M (IRGM) locus and altered expression of guanylate binding proteins (GBPs) with tuberculosis susc

13 oteins to PVs is controlled by IFN-inducible guanylate binding proteins (GBPs), which themselves dock

14 till controlled in HFFs deficient in the p65 guanylate binding proteins GBP1 or GBP2 and the autophag

15 wing number of regulatory networks involving guanylate binding proteins, protein kinases, ubiquitylat

16 examined a complete mouse 65-kilodalton (kD) guanylate-binding protein (Gbp) gene family as part of a

17 ll lines, resulting in the identification of guanylate-binding protein 1 (GBP1) as a potent anti-CSFV

18 library of porcine ISGs, we identify porcine guanylate-binding protein 1 (GBP1) as a potent antiviral

19 Human guanylate-binding protein 1 (hGBP1), the founding member

20 e-like activity factor, and interaction with guanylate-binding protein 1, a host cell factor involved

21 milies in different cell types is the 65-kDa guanylate-binding protein family that is recruited to th

22 man myxovirus resistance protein A and human guanylate-binding protein-1 as markers for the different

23 Patients with primary tumors expressing only guanylate-binding protein-1 exhibited the highest cancer

24 as exclusively induced by IFN-alpha, whereas guanylate-binding protein-1 was strongly induced by IFN-

25 ssion of the IFN-gamma-induced GTPase murine guanylate-binding protein-2 (mGBP-2) can phenocopy this

26 that the interferon-induced GTPase family of guanylate-binding proteins (GBPs) coats Shigella flexner

27 al. demonstrate a critical role for the p65 guanylate-binding proteins (GBPs) in this process during

28 geted by immunity-related GTPases (IRGs) and guanylate-binding proteins (GBPs) upon their induction b

29 IRGM proteins affect the localization of the guanylate-binding proteins (GBPs), a second family of in

30 proteins, the immunity-related GTPases, the guanylate-binding proteins (GBPs), and the very large IF

31 I IFN-associated genes, such as IFN-beta and guanylate-binding proteins (GBPs), are downregulated in

32 An IFN-inducible family of DLPs, the guanylate-binding proteins (GBPs), is involved in antimi

33 ssion of IRF1, which drove the expression of guanylate-binding proteins (GBPs); this led to intracell

34 We show that guanylate-binding proteins are recruited to intracellula

35 family of interferon-induced GTPases called 'guanylate-binding proteins' (GBPs).

36 interferon-inducible GTPases, the so-called guanylate-binding proteins, is required for the full act

37 exposure to g-interferon, including several guanylate-binding proteins.

38 asmic bacteria through a mechanism requiring guanylate-binding proteins.

39 rmans GMP synthase, the second enzyme in the guanylate branch of de novo purine biosynthesis.

40 Bis-(3',5') cyclic di-guanylate (c-di-GMP) is a key bacterial second messenger

41 ein 3 (RD3) is critical in the regulation of guanylate cyclase (GC) signaling and photoreceptor cell

42 studied before and after: (1) inhibition of guanylate cyclase (GC) with and without a NO donor; (2)

43 ny biological effects of NPs are mediated by guanylate cyclase (GC)-coupled NP receptors, NPR-A and N

44 gene encoding the alpha subunit of a soluble guanylate cyclase (Gucy1A3).

45 xide (NO) activates the NO-sensitive soluble guanylate cyclase (NO-GC, sGC) and triggers intracellula

46 assembled domains of nitric oxide-sensitive guanylate cyclase (NOsGC) remains to be determined.

47 Belonging to the class of so-called soluble guanylate cyclase (sGC) activators, cinaciguat and BAY 6

48 Modulation of soluble guanylate cyclase (sGC) activity by nitric oxide (NO) in

49 in (GTN), resulting in activation of soluble guanylate cyclase (sGC) and cGMP-mediated vasodilation.

50 Epigenetic regulation of soluble guanylate cyclase (sGC) beta1 in breast cancer cells.

51 insertion into the beta1 subunit of soluble guanylate cyclase (sGC) beta1, which enables it to assoc

52 Activation of soluble guanylate cyclase (sGC) by the signaling molecule nitric

53 ges of heme coordination in purified soluble guanylate cyclase (sGC) by time-resolved spectroscopy in

54 Soluble guanylyl/guanylate cyclase (sGC) converts GTP to cGMP after bindi

55 RATIONALE: Soluble guanylate cyclase (sGC) heme iron, in its oxidized state

56 uanidine; 10 mumol l(-1) , n = 6) or soluble guanylate cyclase (sGC) inhibitor ODQ (1H-[1,2,4]oxadiaz

57 Soluble guanylate cyclase (sGC) is a heme-containing enzyme that

58 Soluble guanylate cyclase (sGC) is a heterodimer composed of alp

59 Soluble guanylate cyclase (sGC) is the mammalian endogenous nitr

60 Soluble guanylate cyclase (sGC) is the primary nitric oxide (NO)

61 Soluble guanylate cyclase (sGC) is weakly activated by carbon mo

62 Soluble guanylate cyclase (sGC) serves as a receptor for the sig

63 The first-in-class soluble guanylate cyclase (sGC) stimulator riociguat was recentl

64 ery pressure encodes an alpha1-A680T soluble guanylate cyclase (sGC) variant.

65 Soluble guanylate cyclase (sGC), a key enzyme of the nitric oxid

66 (ODQ) resulted in heme oxidation of soluble guanylate cyclase (sGC), as evident from diminished NO-i

67 ine the role of a downstream signal, soluble guanylate cyclase (sGC), in the regulation of NHGU by NO

68 rties with the eukaryotic NO-sensor, soluble guanylate cyclase (sGC), including 5c-NO formation via t

69 loss of the prosthetic haem group of soluble guanylate cyclase (sGC), preventing its activation by ni

70 or a related species that activates soluble guanylate cyclase (sGC), resulting in cGMP-mediated vaso

71 be eliminated by inhibiting hepatic soluble guanylate cyclase (sGC), suggesting that the sGC pathway

72 Soluble guanylate cyclase (sGC), the mammalian NO sensor, transd

73 Soluble guanylate cyclase (sGC), the primary NO receptor, trigge

74 The downstream target of NO, soluble guanylate cyclase (sGC), was in somata in the inner and

75 ignaling proteins in cells including soluble guanylate cyclase (sGC).

76 unctions as the primary activator of soluble guanylate cyclase (sGC).

77 tion of BAY 60-2770, an activator of soluble guanylate cyclase (sGC).

78 ctivity of the downstream NO target, soluble guanylate cyclase (sGC).

79 through activation of the soluble isoform of guanylate cyclase (sGC).

80 tivator of the mammalian hemoprotein soluble guanylate cyclase (sGC).

81 ing the airway smooth muscle enzyme, soluble guanylate cyclase (sGC).

82 tor component, the alpha1 subunit of soluble guanylate cyclase (sGCalpha1), are prone to hypertension

83 protein-coupled receptor kinase 1 (GRK1) and guanylate cyclase 1 (GC1) has been suggested to play a r

84 ophy caused by loss-of-function mutations in guanylate cyclase 1 (GC1), a key member of the phototran

85 ignaling (Nitric Oxide Synthase 3 [NOS3] and Guanylate Cyclase 1, Soluble, Alpha 3 [GUCY1A3]) with a

86 in 2); glucokinase (hexokinase 4) regulator; guanylate cyclase 1, soluble, beta 3; MYST histone acety

87 s (GCAP1 and GCAP2) to their membrane target guanylate cyclase 1.

88 peripherin, early growth response 1, soluble guanylate cyclase 1A3 and placental growth factor protei

89 ing identified a single-base substitution in guanylate cyclase 2D, membrane (retina-specific) gene (G

90 -deficient mice (moderate achromatopsia) and guanylate cyclase 2e-deficient mice (LCA with slower con

91 eotide-gated channel B subunit-deficient and guanylate cyclase 2e-deficient mice decreased about 40%

92 eme- and NO-independent activator of soluble guanylate cyclase [4-([(4-carboxybutyl)[2-(5-fluoro-2-([

93 Ongoing clinical trials have found that guanylate cyclase activating peptides are safe and effec

94 to show a direct association between RD3 and guanylate cyclase activating protein 1 (GCAP1).

95 Modulated by Ca(2+) sensors guanylate cyclase activating proteins 1 and 2 (GCAP1 and

96 Treatment with the soluble guanylate cyclase activator BAY41-2272, a vasorelaxing a

97 hodiesterase-5 inhibitors, and now a soluble guanylate cyclase activator have increased therapeutic o

98 as phosphodiesterase (PDE)-5 inhibitors and guanylate cyclase activators may represent a promising t

99 l-specific knockout of the ANP receptor with guanylate cyclase activity (betaGC-A-KO).

100 Blocking soluble guanylate cyclase activity completely suppresses neurite

101 Therefore, the guanylate cyclase activity of BRI1 is modulated by the k

102 s containing bacterial H-NOX domains exhibit guanylate cyclase activity, but this activity is not inf

103 diazolo[4,3-a]quinoxalin-1-one, a blocker of guanylate cyclase activity.

104 ests additional therapeutic applications for guanylate cyclase agonists.

105 r inhibition of protein kinase A nor soluble guanylate cyclase altered this contractile response.

106 sociation of nitric oxide synthase 1/soluble guanylate cyclase and a higher production of cyclic guan

107 Pharmacological inhibition of soluble guanylate cyclase and NOS activity rapidly induces neuri

108 that requires an atypical O2-binding soluble guanylate cyclase and that is sustained until oxygen lev

109 1) Both nitric oxide synthase 1 and soluble guanylate cyclase are expressed in higher levels in vasc

110 ide/oxygen-binding (H-NOX) domain of soluble guanylate cyclase as a selective NO sensor.

111 Guanylate cyclase C (GC-C) is a transmembrane receptor t

112 Guanylate Cyclase C (GC-C) is an apically-oriented trans

113 osome 12 and then sequenced GUCY2C, encoding guanylate cyclase C (GC-C), an intestinal receptor for b

114 activating mutations in intestinal receptor guanylate cyclase C (GC-C), the genetic cause for the ma

115 Guanylate cyclase C (GUCY2C or GC-C) and its ligands, gu

116 Guanylate cyclase C (GUCY2C) and its hormones guanylin a

117 gous to paracrine hormones of the intestinal guanylate cyclase C (GUCY2C) receptor.

118 out cross-reacting with the human endogenous guanylate cyclase C receptor ligands.

119 a minimally absorbed peptide agonist of the guanylate cyclase C receptor.

120 is an active kinase and also encapsulates a guanylate cyclase catalytic centre.

121 Mutating the guanylate cyclase center of PSKR1 impairs seedling growt

122 A guanylate cyclase construct containing the juxta-membran

123 affects the efficacy of soluble/particulate guanylate cyclase coupling to cGMP in cardiac dysautonom

124 n did wild-type Brucella or the low-c-di-GMP guanylate cyclase DeltacgsB mutant.

125 o be observed for any member of the membrane guanylate cyclase family.

126 opportunities aimed at activation of soluble guanylate cyclase for multiple cardiovascular indication

127 The soluble guanylate cyclase GCY-35 is required for high oxygen to

128 BAG transduction pathway, the receptor-type guanylate cyclase GCY-9, suffices to confer cellular sen

129 ing of a sensory receptor, the receptor-type guanylate cyclase GCY-9, to cilia in chemosensory neuron

130 ide-gated ion channels and the receptor-type guanylate cyclase GCY-9.

131 These neurons express the soluble guanylate cyclase Gucy1b2 and the cation channel Trpc2.

132 psis, whereas levels and activity of soluble guanylate cyclase increase.

133 2)O(2)-induced dilation, whereas the soluble guanylate cyclase inhibitor ODQ had no effect.

134 sensory neurons, the odorant receptor ONE-GC guanylate cyclase is a central transduction component of

135 d suggest that activation of a receptor-type guanylate cyclase is an evolutionarily conserved mechani

136 is also unknown how binding of NO to heme in guanylate cyclase is communicated to the catalytic domai

137 of cyclic guanosine monophosphate (cGMP) by guanylate cyclase is of critical importance to gastroint

138 of mice lacking one of the two NO-sensitive guanylate cyclase isoforms [NO-GC1 knockout (KO) or NO-G

139 hibited pathological differentiation via the guanylate cyclase NPR2 (natriuretic peptide receptor 2)

140 e current study the conformational change of guanylate cyclase on activation by NO was studied using

141 , as occurs at the Fe(2+) centres of soluble guanylate cyclase or cytochrome c oxidase.

142 iomyocyte cGMP synthesis via an eNOS/soluble guanylate cyclase pathway.

143 n of COX, but was independent of the soluble guanylate cyclase pathway.

144 rived nitric oxide and activation of soluble guanylate cyclase promotes endothelial quiescence and go

145 ide is a novel therapeutic agent, which is a guanylate cyclase receptor agonist that stimulates water

146 evidence indicates that membrane-associated guanylate cyclase receptors regulate intestinal epitheli

147 tients, with associated increases in soluble guanylate cyclase responsiveness to NO.

148 target proteins beta-PIX, plakophilin-4, and guanylate cyclase soluble subunit alpha-2 using colocali

149 ervious pulmonary embolism, treatment with a guanylate cyclase stimulator normalized pulmonary hemody

150 rectomy (PEA) who were receiving the soluble guanylate cyclase stimulator riociguat.

151 ulmonary vasodilator reserve using a soluble guanylate cyclase stimulator, BAY 41-8543.

152 Riociguat, a soluble guanylate cyclase stimulator, has been shown in a phase

153 hypothesized that riociguat, a novel soluble guanylate cyclase stimulator, would have beneficial hemo

154 member of a new class of compounds (soluble guanylate cyclase stimulators), has been shown in previo

155 sts, phosphodiesterase-5 inhibitors, soluble guanylate cyclase stimulators, prostacyclin analogues, a

156 and GCAP2 to the full-length membrane-bound guanylate cyclase type 1.

157 between nitric oxide synthase 1 and soluble guanylate cyclase were determined.

158 ) production with l-NA (100 mum) and soluble guanylate cyclase with 1H-[1,2,4]oxadiazolo[4,3-a]quinox

159 AP2 bound to different regions on the target guanylate cyclase with submicromolar affinity (apparent

160 The homeobox gene Emx1 is expressed in three guanylate cyclase(+) populations, two located in the MOE

161 receptor ROS-GC1 (rod outer segment membrane guanylate cyclase) is a vital component of phototransduc

162 itric oxide synthase 1 (and possibly soluble guanylate cyclase) may represent a valuable alternative

163 of AxCYTcp, the eukaryotic NO sensor soluble guanylate cyclase, and the ferrocytochrome c/cardiolipin

164 ANF-RGC is the prototype membrane guanylate cyclase, both the receptor and the signal tran

165 ndothelial nitric-oxide synthase and soluble guanylate cyclase, but direct effects on VEGFR2 have not

166 rtension, riociguat, a stimulator of soluble guanylate cyclase, has proven efficacious.

167 by the kinase while cGMP, the product of the guanylate cyclase, in turn inhibits BRI1 kinase activity

168 cological inhibitors of NO synthase, soluble guanylate cyclase, or cGMP-dependent protein kinases (PK

169 P2Y12 GPVI, PAR1/PAR4, TP, IP receptors, and guanylate cyclase, respectively, in Factor Xa-inhibited

170 l delivery of AAV5 vectors containing murine guanylate cyclase-1 (GC1) cDNA driven by either photorec

171 Treatment with PKG inhibitor and deletion of guanylate cyclase-1 (GC1), the enzyme producing cGMP in

172 e elucidated this dependency by showing that guanylate cyclase-1 is a novel rhodopsin-binding protein

173 Indeed, we demonstrated that guanylate cyclase-1, producing the cGMP second messenger

174 ons in GUCY2D, the gene that encodes retinal guanylate cyclase-1.

175 We studied guanylate cyclase-activating protein 1 (GCAP1) as an exa

176 sites (EF-hands) of the GUCA1A gene encoding guanylate cyclase-activating protein 1 (GCAP1) cause slo

177 o the amino acid substitution p.L176F in the guanylate cyclase-activating protein 1 (GCAP1).

178 We tested direct binding of guanylate cyclase-activating proteins (GCAP1 and GCAP2)

179 Guanylate cyclase-activating proteins (GCAPs) link cGMP

180 ylin in the brain and activates the receptor guanylate cyclase-C (GC-C) to reduce food intake and pre

181 n these patients presumably by activation of guanylate cyclase-C (GC-C), which stimulates production

182 naclotide is a minimally absorbed agonist of guanylate cyclase-C (GUCY2C or GC-C) that reduces sympto

183 a minimally absorbed peptide agonist of the guanylate cyclase-C receptor that stimulates intestinal

184 y absorbed, 14-amino acid peptide agonist of guanylate cyclase-C, has shown benefit in a proof-of-con

185 iac natriuretic peptides ANP and BNP and the guanylate cyclase-linked natriuretic peptide receptors N

186 ration through activation of the particulate guanylate cyclase-linked natriuretic peptide receptors N

187 ly to enhance GABA release through a soluble guanylate cyclase-mediated pathway.

188 st sensitive target of NO signaling, soluble guanylate cyclase.

189 ivate, and the subsequent generation cGMP by guanylate cyclase.

190 in sepsis and its relationship with soluble guanylate cyclase.

191 s a vital ANF signal transducer motif of the guanylate cyclase.

192 ers include the mammalian NO sensor, soluble guanylate cyclase.

193 capability to the regulatory site in soluble guanylate cyclase.

194 an higher apparent affinity with its target guanylate cyclase.

195 ibitors of Gbetagamma, Akt, NOS, and soluble guanylate cyclase.

196 from targeting of the haem moiety of soluble guanylate cyclase.

197 understanding gastrointestinal transmembrane guanylate cyclase/cGMP physiology has recently accelerat

198 l for therapeutic manipulation of intestinal guanylate cyclase/cGMP signaling for the correction of c

199 enated myoglobin activates canonical soluble guanylate cyclase/cGMP signaling pathways.

200 ansmitter release from photoreceptors by the guanylate cyclase/PDE6 pair in phototransduction.

201 rons counterbalance each other via different guanylate cyclases (GCYs) to control lifespan balance.

202 Soluble guanylate cyclases (sGCs) are gas-binding proteins that

203 Significance statement: Soluble guanylate cyclases (sGCs) control essential and diverse

204 A canonical Galpha-protein, together with guanylate cyclases and cGMP-gated channels, is needed fo

205 litating the stability and/or trafficking of guanylate cyclases and maintaining ER and mitochondrial

206 y NO, CO, and O(2), suggesting that atypical guanylate cyclases and NO-sensitive guanylate cyclases h

207 Transmembrane guanylate cyclases are also important in gastrointestina

208 Rom1 or peripherin/rds; however, the retinal guanylate cyclases GC1 and GC2 were severely affected in

209 atypical guanylate cyclases and NO-sensitive guanylate cyclases have a common molecular mechanism for

210 and humans suggests a role for transmembrane guanylate cyclases in intestinal fluid secretion as well

211 ailing the role of a subset of transmembrane guanylate cyclases in the pathophysiology of intestinal

212 Atypical soluble guanylate cyclases mediating O(2) responses also contrib

213 Our data suggest GLB-5 and the soluble guanylate cyclases operate in close proximity to sculpt

214 ation of GCY-33 and GCY-35, atypical soluble guanylate cyclases that act as O2 sensors, to the dendri

215 ted process and requires membrane-associated guanylate cyclases, but not typical phosphodiesterases.

216 fine a new transduction paradigm of membrane guanylate cyclases.

217 cyclic GMP-gated cation channels and distal guanylate cyclases.

218 re tRNA(His) has at its 5'-terminus an extra guanylate, designated as G(-1).

219 phosphorylation of PSD-95 at Ser-561 in its guanylate kinase (GK) domain, which is mediated by the p

220 SAP102 contains PDZ, SH3, and guanylate kinase (GK)-like domains, which mediate specif

221 e molecular interaction between (p)ppGpp and guanylate kinase (GMK), revealing the importance of this

222 3 (SH3) domain, and a region of homology to guanylate kinase (GUK); the structure of this core motif

223 s, the discs large (DLG)-membrane-associated guanylate kinase (MAGUK) family of scaffolding proteins

224 ptic density-95 (PSD-95) membrane-associated guanylate kinase (MAGUK) family of scaffolding proteins

225 KEY POINTS: The membrane-associated guanylate kinase (MAGUK) family of synaptic scaffolding

226 The membrane-associated guanylate kinase (MAGUK) family of synaptic scaffolding

227 The membrane-associated guanylate kinase (MAGUK) homologs PSD-95/SAP90, PSD-93/c

228 termined previously that membrane-associated guanylate kinase (MAGUK) protein discs large homolog 5 (

229 of the Discs large (DLG)-membrane-associated guanylate kinase (MAGUK) protein family regulate these p

230 t excitatory synapses by membrane-associated guanylate kinase (MAGUK) proteins regulates synapse deve

231 he zonula occludens (ZO) membrane-associated guanylate kinase (MAGUK) proteins ZO-1, -2, and -3.

232 ayed impaired binding to membrane-associated guanylate kinase (MAGUK) proteins.

233 ptors and enzymes around Membrane Associated Guanylate Kinase (MAGUK) scaffold proteins are a paradig

234 reported to bind to the membrane-associated guanylate kinase (MAGUK) scaffolding proteins, as well a

235 teins of the PSD-95-like membrane-associated guanylate kinase (PSD-MAGUK) family are vital for traffi

236 itment domain-containing membrane-associated guanylate kinase 1 (CARMA1) and/or the Toll-like recepto

237 spase-recruitment domain membrane-associated guanylate kinase 1 (CARMA1) signalosome through the coor

238 membrane complex with a membrane-associated guanylate kinase and AKAP5, which constitutively attenua

239 revealed that specific amino acid changes in guanylate kinase and in the beta and beta' subunits of R

240 analyzed the dynamic behavior of the enzyme guanylate kinase as it evolved into the GK protein inter

241 nts revealed 2 binding surfaces on the beta4 guanylate kinase domain contributing to a 156 +/- 18 mic

242 a loss-of-function mutant mouse lacking the guanylate kinase domain of PSD-95 (PSD-95(GK)), we analy

243 A fragment comprising the SH3 domain and the guanylate kinase domain of synapse-associated protein 10

244 /Discs large/ZO-1 (PDZ)-Src homology 3 (SH3)-guanylate kinase domain sequence.

245 ort polybasic segment at the boundary of the guanylate kinase domain that slows down channel inactiva

246 -Subunits contain one Src homology 3 and one guanylate kinase domain, flanked by variable regions wit

247 se at the dynamic interaction of PDZ and SH3-guanylate kinase domains in membrane-associated guanylat

248 ramolecular interactions between the SH3 and guanylate kinase domains play a role in the stability of

249 lg1, zona occludens-1) domains, the PDZ3 and guanylate kinase domains were required.

250 ined beta isoforms, which consist of SH3 and guanylate kinase domains.

251 The guanylate kinase enzyme (GK(enz)), which catalyzes phosp

252 he leading member of the membrane-associated guanylate kinase family of proteins, which are defined b

253 proteins, members of the membrane-associated guanylate kinase homolog (MAGUK) protein family, which a

254 ule (S-SCAM; also called membrane-associated guanylate kinase inverted-2 and atrophin interacting pro

255 itment domain-containing membrane-associated guanylate kinase protein (CARMA)3 is specifically expres

256 t serine protein kinase; membrane-associated guanylate kinase protein (MAGI)-1, MAGI-2, and MAGI-3],

257 We show here that membrane-associated guanylate kinase protein Dlg5 is required for proper bra

258 and other members of the membrane-associated guanylate kinase protein family, as well as Scribble.

259 , we have identified the membrane-associated guanylate kinase protein membrane palmitoylated protein

260 protein-97 (SAP97) is a membrane-associated guanylate kinase scaffolding protein expressed in cardio

261 major glutamate receptor membrane-associated guanylate kinase scaffolds expressed in the young superf

262 a oligomerization reside in 3 regions of the guanylate kinase subdomain of MAGUK.

263 identify members of the membrane-associated guanylate kinase with inverted orientation (MAGI) and PS

264 ntaining protein MAGI-1 (membrane-associated guanylate kinase with inverted orientation protein-1) an

265 LPA(2) interacts with membrane-associated guanylate kinase with inverted orientation-3 (MAGI-3) an

266 Discs Large 1, a MAGUK (Membrane Associated Guanylate Kinase) family member that is the highly conse

267 nd recruitment of MAGUK (membrane-associated guanylate kinase) scaffolding proteins or NMDA receptors

268 ly, we show that MAGI-2 (membrane-associated guanylate kinase), a scaffold protein required for PTEN

269 overlaps with its MAGUK (membrane-associated guanylate kinase)-binding domain.

270 ng HIV-reverse transcriptase (RT), adenylate/guanylate kinase, and human DNA polymerase gamma.

271 itment domain-containing membrane-associated guanylate kinase, initiates a unique signaling cascade v

272 PSD-95, a membrane-associated guanylate kinase, is the major scaffolding protein at ex

273 PSD-95, a membrane-associated guanylate kinase, is the major scaffolding protein in th

274 s, we found that loss of membrane associated guanylate kinase, WW and PDZ domain containing 2 and pro

275 ase-causing mutations in membrane-associated guanylate kinase, WW, and PDZ domain-containing 2 (MAGI2

276 Here we report that guanylate kinase-associated protein (GKAP; also known as

277 are formed by a Src homology 3 domain and a guanylate kinase-like (GK) domain connected through a va

278 hare a highly homologous membrane associated guanylate kinase-like (MAGUK) domain that binds to alpha

279 lating interactions with their COOH-terminal guanylate kinase-like domains (GKs).

280 Membrane-associated guanylate kinases (MAGUKs) are major components of the p

281 nsity (PSD)-95 family of membrane-associated guanylate kinases (MAGUKs) are major scaffolding protein

282 The Membrane Associated Guanylate Kinases (MAGuKs) are scaffold proteins at cell

283 dance of PSD-95 or other membrane-associated guanylate kinases (MAGUKs) drives the bidirectional chan

284 Membrane-associated guanylate kinases (MAGUKs) organize protein complexes at

285 ecipitates Kv1.2 and the membrane-associated guanylate kinases (MAGUKs) PSD-93 and PSD-95.

286 (discs large) family of membrane-associated guanylate kinases (MAGUKs) that are components of the po

287 Membrane-associated guanylate kinases (MAGUKs), including SAP102, PSD-95, PS

288 Membrane-associated guanylate kinases (MAGUKs), which are essential proteins

289 n-binding domain found in membrane associate guanylate kinases that function in mitotic spindle orien

290 GPR30 interacted with membrane-associated guanylate kinases, including SAP97 and PSD-95, and prote

291 nylate kinase domains in membrane-associated guanylate kinases.

292 (TARPs) and PSD-95-like membrane-associated guanylate kinases.

293 d recruitment domain and membrane-associated guanylate-like kinase domain-containing protein 3; membr

294 ing proteins include the membrane-associated guanylate-like kinases [postsynaptic density protein of

295 ent inhibition of invasion to suppression of guanylate metabolism.

296 We find that pharmacological inhibitors of guanylate nucleotide synthesis have selective deleteriou

297 ction maintaining the cellular adenylate and guanylate nucleotide.

298 aasl knock-out and consequent starvation for guanylate nucleotides.

299 or balancing the intracellular adenylate and guanylate pools.

300 idinyl-N)-GMP intermediate; (ii) transfer of guanylate to a polynucleotide 3'-phosphate to form a pol

301 how the synergy of the binding of MSG and 5'-guanylate to tongue taste tissue mirror this hallmark pe